14:41 , Mar 7, 2019 |  BC Innovations  |  Translation in Brief

Blocking B cell vesicles to enhance chemotherapy

Blocking extracellular vesicles derived from B cells could offer a new therapeutic avenue to enhance the efficacy of chemotherapy for cancer, according to a Zhejiang University study. Chemotherapy reduces antitumor immunity by inducing systemic immunosuppression....
20:45 , Dec 21, 2018 |  BC Week In Review  |  Company News

Surface drops after deprioritizing lead product

Surface Oncology Inc. (NASDAQ:SURF) was off $3.52 (48%) to $3.89 on Dec. 19 after the company said late Dec. 18 it will deprioritize Phase I candidate SRF231, one of its two clinical programs. The immunotherapy...
23:26 , Dec 19, 2018 |  BC Extra  |  Company News

Surface drops after deprioritizing lead product

Surface Oncology Inc. (NASDAQ:SURF) was off $3.52 (48%) to $3.89 on Wednesday after the company said late Tuesday it will deprioritize Phase I candidate SRF231, one of its two clinical programs. The immunotherapy company said...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
19:46 , Nov 1, 2018 |  BC Innovations  |  Emerging Company Profile

Secarna’s next-gen oligos

Secarna Pharmaceuticals GmbH’s antisense oligonucleotides for immuno-oncology could have better tissue penetration than small molecules and antibodies against the same targets. The company was established in 2015 by the founders and investors who launched antisense...
19:01 , Oct 26, 2018 |  BC Week In Review  |  Company News

AstraZeneca gets rights, options to Innate immuno-oncology therapies

AstraZeneca plc (LSE:AZN; NYSE:AZN) expanded its next generation immuno-oncology pipeline on Oct. 23, gaining rights and options to a basket of therapies from Innate Pharma S.A. (Euronext:IPH). In return, Innate gained U.S. and European commercialization...
23:17 , Oct 23, 2018 |  BC Extra  |  Company News

AstraZeneca gets rights, options to basket of next-gen immuno-oncology therapies from Innate

AstraZeneca plc (LSE:AZN; NYSE:AZN) expanded its next generation immuno-oncology pipeline on Tuesday, gaining rights and options to a basket of therapies from Innate Pharma S.A. (Euronext:IPH). In return, Innate gained U.S. and European commercialization rights...
23:41 , Apr 26, 2018 |  BC Innovations  |  Product R&D

Brake for gas

Elpiscience Biopharmaceuticals Co. Ltd. has emerged from stealth mode with an unconventional bispecific that simultaneously removes the brakes and steps on the gas for antitumor immunity, but only inside tumors. The goal is to upstage...
02:46 , Mar 24, 2018 |  BioCentury  |  Product Development

Optimism for A2A

Once considered solely a neurology target, the adenosine pathway has attracted interest in immuno-oncology based on its ability to control whether immune cells adopt a stimulatory or suppressive phenotype. The early results from A2A receptor...